CSIMarket
 
Seagen Inc   (SGEN)
Other Ticker:  
 
 
Price: $228.7400 $-0.16 -0.070%
Day's High: $228.96 Week Perf: 4.77 %
Day's Low: $ 228.74 30 Day Perf: 7.29 %
Volume (M): 20,075 52 Wk High: $ 228.96
Volume (M$): $ 4,592,047 52 Wk Avg: $203.67
Open: $228.93 52 Wk Low: $184.69



 Market Capitalization (Millions $) 43,034
 Shares Outstanding (Millions) 188
 Employees 2,700
 Revenues (TTM) (Millions $) 2,300
 Net Income (TTM) (Millions $) -750
 Cash Flow (TTM) (Millions $) 61
 Capital Exp. (TTM) (Millions $) 161

Seagen Inc
Seagen Inc., formerly known as Seattle Genetics, is an American biotechnology company founded in 1998 and headquartered in Bothell, Washington.
The company's primary focus is on developing and commercializing innovative, targeted therapies for the treatment of cancer and other challenging diseases.
Seagen's primary product is ADCETRIS (brentuximab vedotin), which is an antibody-drug conjugate (ADC) that delivers the chemotherapy drug directly to cancer cells.
ADCETRIS has been approved for the treatment of several different types of cancer, including Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and primary cutaneous anaplastic large cell lymphoma.
Seagen has also developed several other ADCs that are in various stages of clinical development.
These include tucatinib, which is in Phase 3 clinical trials for the treatment of HER2-positive breast cancer; ladiratuzumab vedotin, which is in Phase 2 trials for the treatment of triple-negative breast cancer; and datopotamab deruxtecan, which is in Phase 1 trials for the treatment of various solid tumors.
Aside from ADCs, Seagen has also developed proprietary technologies for antibody-drug conjugate production, including its proprietary linker and cytotoxic payload technologies that enable a higher therapeutic index and greater specificity for tumor cells.
Seagen has partnerships with various pharmaceutical companies, including Takeda Pharmaceutical Company, Astellas Pharma, and Merck.
The company has also received funding from the National Cancer Institute and various venture capital firms.
In conclusion, Seagen Inc.
is a biotechnology company that specializes in the development and commercialization of targeted therapies for cancer and other diseases, with a primary focus on antibody-drug conjugates.
The company's flagship product is ADCETRIS, and it has several other products in various stages of clinical development.
Its proprietary technologies for ADC production give it a unique advantage in the field, and it has partnerships and funding from various large pharmaceutical companies and organizations.


   Company Address: 21823 30th Drive SE Bothell 98021 WA
   Company Phone Number: 527-4000   Stock Exchange / Ticker: NASDAQ SGEN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Pfizer's Transcendent Union with Seagen: Paving the Way for Revolutionary Cancer Treatments

Published Thu, Dec 14 2023 12:39 PM UTC

Pfizer Completes Acquisition of Seagen: Advancing Transformative Cancer Medicines
In a significant move towards advancing cancer treatments, Pfizer Inc. (NYSE: PFE) announced today the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a renowned global biotechnology company dedicated to discovering, developing, and commercializing transformative can...

Merger and Acquisition

Pfizer's Acquisition of Seagen Receives Regulatory Green Light, Set to Close on December 14th

Published Tue, Dec 12 2023 11:45 AM UTC

Breaking News: Pfizer's Acquisition of Seagen Receives Regulatory Approvals, Expected to Close on December 14th
New York, December 11, 2023 - Pfizer Inc. (NYSE: PFE) announced today that it has successfully completed the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to its pending acquisition of Seagen Inc. (NASDA...

Product Service News

ADCETRIS Plus Novel Immunotherapy Combination Shows Promising Results in Phase 2 Trial for Hodgkin Lymphoma Patients

Published Mon, Dec 11 2023 12:30 AM UTC


BOTHELL, Wash. - Seagen Inc. (NASDAQ: SGEN) has announced groundbreaking findings from a Phase 2 trial evaluating the combination of its antibody-drug conjugate (ADC), ADCETRIS (brentuximab vedotin), with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) as a first-line treatment for early and advanced stage classical Hodg...

Product Service News

Seagen Unleashes Groundbreaking Immunotherapy Combination and Novel ADC for Solid Tumors

Published Fri, Nov 3 2023 4:00 PM UTC

Seagen's ADCETRIS Immunotherapy Combination Shows Promise in Solid Tumors, and Unveils Novel CD30-Directed Antibody-Drug Conjugate
In a groundbreaking development, Seagen Inc. unveiled exciting data on their immunotherapy combination involving ADCETRIS (brentuximab vedotin) at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The combination of ADCETRIS...

Seagen Inc

Seagen Inc's Earnings Reach Extraordinary Heights, Surpassing Industry Peers Amidst Uncertain Future



Over the last five trading days, Seagen Inc experienced a decline of -1.52% in shares, bringing the year-to-date performance to an impressive 66.39%. In addition, the company's shares are 1.5% short of their 52-week high. However, these recent financial results have raised concerns about the company's future trajectory.
Strong Revenue Growth:
Seagen Inc recently announced a surge in revenue for the period between July and September 2023. The revenue recorded a remarkable 27.112% increase, reaching $648.65 million compared to the same period a year earlier. This growth significantly outpaced that of its peers in the biotechnology and pharmaceuticals sector. In fact, the two other major players in the sector reported a revenue growth of only 4.18% relative to the third quarter of 2022.






 

Seagen Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com